OncoMatch/Clinical Trials/NCT07779018
CD19/CD22 CAR-T Consolidation in R/R Aggressive B-Cell Lymphoma After Second-Line Therapy
Is NCT07779018 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies CD22/CD19 CAR-T cell immunotherapy for lymphoma.
Treatment: CD22/CD19 CAR-T cell immunotherapy — The purpose of this study is to determine the efficacy and safety of CD22/CD19-targeted CAR-T cell immunotherapy as consolidation therapy after second-line treatment in patients with high-risk aggressive B-cell lymphoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Primary Central Nervous System Lymphoma
Biomarker criteria
Required: CD19 expression (positive)
CD19 and/or CD22-positive large B-cell lymphoma (LBCL)
Required: CD22 expression (positive)
CD19 and/or CD22-positive large B-cell lymphoma (LBCL)
Allowed: MYC rearrangement
FISH confirmed high-grade B-cell lymphoma with double or triple strikes, accompanied by MYC and BCL2 and/or BCL6 rearrangements
Allowed: BCL2 rearrangement
FISH confirmed high-grade B-cell lymphoma with double or triple strikes, accompanied by MYC and BCL2 and/or BCL6 rearrangements
Allowed: BCL6 rearrangement
FISH confirmed high-grade B-cell lymphoma with double or triple strikes, accompanied by MYC and BCL2 and/or BCL6 rearrangements
Allowed: MYC expression
Immunohistochemistry suggests dual expression of MYC and BCL-2 (recommended dual expression threshold is MYC ≥ 40%, BCL2 ≥ 50%)
Allowed: BCL2 expression
Immunohistochemistry suggests dual expression of MYC and BCL-2 (recommended dual expression threshold is MYC ≥ 40%, BCL2 ≥ 50%)
Allowed: CD5 expression
Immunohistochemical CD5 positivity
Allowed: TP53 mutation
Gene sequencing shows TP53 mutation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: second-line chemotherapy — induction treatment
disease has achieved complete response (CR) after induction treatment with a standard second-line chemotherapy regimen
Cannot have received: CAR-T cell therapy
Have received any form of chimeric antigen receptor cell therapy or other genetically modified T cell therapy
Lab requirements
Blood counts
HGB ≥ 60g/L; absolute neutrophil count ≥ 1000/μl; platelet count ≥ 45000/μl
Kidney function
Serum creatinine ≤ 1.5x ULN or creatinine clearance rate ≥ 60 mL/min
Liver function
Total bilirubin (TBIL) ≤ 1.5x ULN (except Gilbert's syndrome); ALT/AST ≤ 2.5x ULN
Cardiac function
LVEF ≥ 50%; ECHO confirms no pericardial effusion and no clinically significant arrhythmia
Liver and kidney function, as well as heart and lung function, meet the following requirements: 1) Total bilirubin (TBIL) ≤ 1.5 times the upper limits of normal (ULN), except for subjects with Gilbert's syndrome; 2) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN; 3) Serum Creatinine (Cr) ≤ 1.5 times ULN or Creatinine Clearance Rate (CCr) ≥ 60mL/min, estimated based on the Cockcroft Gault formula; 4) The left ventricular ejection fraction (LVEF) of the heart is ≥ 50%. Echocardiography (ECHO) confirms no pericardial effusion and no clinically significant arrhythmia; 5) Baseline transcutaneous oxygen saturation under indoor ventilation>92%; 6) No clinically significant pleural effusion
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07779018 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CAR-T cell therapy disqualifies patients from enrollment.
Does this trial require CD19?
Yes, CD19 expression is a required biomarker for enrollment.
Does this trial require CD22?
Yes, CD22 expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 85 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages